Bristol Myers Squibb's ZENBEXUS Combination Therapy Shows Superior Survival in Multiple Myeloma Trial
Event summary
- Bristol Myers Squibb's ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone (ZDd) demonstrated a 51% reduction in the risk of disease progression or death compared to standard of care in relapsed/refractory multiple myeloma.
- The Phase 3 EXCALIBER-RRMM study showed median progression-free survival of 42 months for ZDd vs. 20 months for the standard regimen.
- Results were presented at the International Myeloma Society's 23rd annual meeting and published in Lancet Oncology.
- ZENBEXUS is currently approved under accelerated approval contingent on confirmatory trial results.
- The study included 800 patients with a median follow-up of 23 months.
The big picture
This positive Phase 3 result reinforces Bristol Myers Squibb's leadership in multiple myeloma treatment, particularly in the relapsed/refractory space. The combination therapy's superior progression-free survival could reshape treatment paradigms, potentially capturing market share from existing regimens. The company's targeted protein degradation platform continues to yield promising clinical outcomes, positioning it as a key player in oncology innovation.
What we're watching
- Regulatory Pathway
- Whether the positive Phase 3 results will lead to full approval and expanded indications for ZENBEXUS beyond the current accelerated approval.
- Market Positioning
- How Bristol Myers Squibb positions ZENBEXUS against existing multiple myeloma treatments in the relapsed/refractory setting.
- Commercialization Strategy
- The pace at which Bristol Myers Squibb can integrate ZENBEXUS into treatment protocols, particularly in community care settings.
Related topics
